Fondazione IRCCS Istituto Nazionale Tumori
Fondazione IRCCS Istituto Nazionale Tumori
Milan, Italy10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Adenoma, Islet Cell, Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, neuroendocrine neoplasm, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 / Phase 3 | 2026-09-29 | NCT06943755 | |
| HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Active, not recruiting | Phase 2 | 2026-09-01 | NCT04619004 | |
| Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-08-26 | NCT04656652 | |
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, uveal disorder, uveal melanoma | Active, not recruiting | Phase 2 | 2026-03-16 | NCT05907954 | |
| International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, brain cancer, brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioma, medulloblastoma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 / Phase 3 | 2025-12-04 | NCT02066220 | |
| RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study | HER2 positive breast carcinoma, Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast carcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2025-06-22 | NCT07030569 | |
| Sentinel Node Vs Observation After Axillary Ultra-souND | Early Stage Breast Carcinoma | Active, not recruiting | Not applicable | 2024-11-25 | NCT02167490 | |
| Italian Observational Study on CAR-T Therapy for Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Recruiting | Not stated | 2024-04-01 | NCT06339255 | |
| AIOCC Italian Registry on Head and Neck Carcinomas | head and neck carcinoma | Recruiting | Not stated | 2024-03-08 | NCT06248944 | |
| FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Not yet recruiting | Phase 2 | 2023-01-30 | NCT05703997 |